New Senior Executives appointed at Sanofi

SanofiSanofi (EURONEXT : SAN ; NYSE : SNY) announced the appointment of Greg Irace, currently President and CEO of Sanofi's US operations, to the newly created role of Senior Vice President, Global Services. In his new role, Greg will lead the Global Information Systems function, be responsible for shared support functions across all Sanofi businesses in North America and play a key role in the development of a global strategy for shared services. Greg will report to Jérôme Contamine, Executive Vice President, Chief Financial Officer, and will continue to be a member of the Global Management Committee. He will be based in Bridgewater, New Jersey.

Jérôme Contamine, Executive Vice President, Chief Financial Officer, Sanofi, commented: "The integration of Genzyme and Merial gives Sanofi the opportunity to create a platform of shared support functions to serve Sanofi's five North American businesses and its more than 20,000 employees. I am confident that Greg's dedication and the leadership he has shown in his previous roles will result in his leading this new organization to great success."

Anne C. Whitaker will join Sanofi as President, North America, Pharmaceuticals, effective September 1, 2011. She will report to Hanspeter Spek, President, Global Operations and will join the Global Management Committee. She will be based in Bridgewater, New Jersey.

Hanspeter Spek, President, Global Operations, Sanofi, declared: "The knowledge and experience Anne has gained through her previous roles in Sales, Marketing and Leadership Development in the Pharmaceutical industry, particularly in the United States, make her ideally suited to drive the renewed growth of our pharmaceutical operations in North America."

Anne joins Sanofi from GSK, where she was Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology, since 2009. Anne holds a Bachelors degree in Chemistry and Business Administration from the University of North Alabama. She began her career at Delta Communications and joined the Upjohn Company in 1991 as a metabolic disease specialist. She joined GSK in 1992 as a sales representative and held various positions in Sales and Training. In 2001, she became Vice President of Critical and Supportive Care, a Business Division based in Pennsylvania, before being appointed Senior Vice President of Leadership and Organization Development, based in London, England, from 2008 to 2009.

Greg Irace holds a B.S. in accounting from Albany State University. He began his career at Price Waterhouse in 1980 and received his CPA in 1982. He spent 11 years at Price Waterhouse becoming a Senior Audit Manager in 1988, and a Senior Manager in the Corporate Finance Department in 1989. In 1991, he joined Sterling Winthrop Inc. and became in 1993 Director of Financial Planning and Analysis, and then Chief Financial Officer of Sanofi's Pharmaceutical Operations in the United States in 1994. He has held his current responsibilities for the US operations since 2007.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...